Answers are grounded in this paper and cite their sources.
Sir, The emergence of multidrug-resistant Salmonella infection is an ever-increasing problem and is a cause for serious global concern. Resistance to third-generation cephalosporins in Salmonella has been attributed to the production of extended-spectrum β-lactamases (ESBLs), but resistance mediated by AmpC and KPC or metallo-β-lactamases (‘MBLs’) has also been reported.1 In particular, the AmpC β-lactamases reported in non-typhoidal Salmonella (NTS) are derivatives of CMY, DHA-1 and ACC-1,1 although ACC-1-producing Salmonella Typhi has been recently identified in India.2 A Salmonella enterica serovar Typhi (designated B729) isolate was isolated from the blood culture of a child admitted to a hospital in Salem, Tamil Nadu, in December 2009. Species identification and antibiotic susceptibility were performed using an automated system (VITEK-2, bioMérieux Inc.). The isolate was further confirmed by serotyping using specific antiserum. This isolate was resistant to all the β-lactams (except carbapenems), but susceptible to non-β-lactam antibiotics. MICs of various antibiotics were determined using the agar dilution method, and susceptibility data were interpreted using EUCAST breakpoints (version 1.3; January 2011), while tetracycline and nalidixic acid susceptibilities were interpreted as recommended by CLSI guidelines (January 2011), as EUCAST breakpoints are not defined. B729 showed elevated MICs of all the β-lactams except carbapenems (<0.25 mg/L), co-trimoxazole (<1 mg/L), chloramphenicol (4 mg/L), aminoglycosides (<0.5 mg/L), tetracycline (2 mg/L), nalidixic acid (2 mg/L) and ciprofloxacin (<0.015 mg/L). The presence of AmpC was determined by phenotypic methods, namely an AmpC disc test and a modified three-dimensional test.2 PCR assays for the genes encoding β-lactamases3 showed that B729 carried blaCMY-2. In addition, PCR mapping experiments4 and sequencing analysis revealed that the blaCMY-2 was flanked by ISEcp1 and a blc gene, similar to the NTS isolates previously reported in the USA, Taiwan and Europe. Plasmid analysis using the Kieser technique revealed that B729 harboured three plasmids, with respective sizes of 90, 70 and 25 kb, using Escherichia coli NCTC 50192 as a reference marker. To determine whether the AmpC phenotype was transferable, transconjugation experiments were attempted using a ciprofloxacin-resistant clinical isolate of Salmonella Typhimurium and the azide-resistant E. coli J53 as the recipient. Transconjugants were selected on MacConkey agar plates containing cefotaxime (2 mg/L) and ciprofloxacin (1 mg/L) or sodium azide (200 mg/L). The AmpC phenotype was successfully transferred to both of the species tested. The plasmids of the transconjugants showing an AmpC phenotype were typed by PCR-based replicon typing.5 The plasmid profile revealed that the E. coli J53-p729A transconjugant carried a blaCMY-2-positive 70 kb plasmid that belonged to the IncA/C incompatibility type (Table 1). Characteristics of Salmonella Typhi B729, transconjugants, E. coli J53 and Salmonella Typhimurium (clinical strain) AMP, ampicillin; AMC, amoxicillin/clavulanic acid; CRO, ceftriaxone; CTX/CLA, cefotaxime/clavulanic acid; CAZ, ceftazidime; FOX, cefoxitin; TZP, piperacillin/tazobactam; FT, frequency of transfer or transconjugation efficiency. Characteristics of Salmonella Typhi B729, transconjugants, E. coli J53 and Salmonella Typhimurium (clinical strain) AMP, ampicillin; AMC, amoxicillin/clavulanic acid; CRO, ceftriaxone; CTX/CLA, cefotaxime/clavulanic acid; CAZ, ceftazidime; FOX, cefoxitin; TZP, piperacillin/tazobactam; FT, frequency of transfer or transconjugation efficiency. To assess if plasmid p729 encoding blaCMY-2 was stable, both the donors and transconjugants were passaged serially up to 10 times on Mueller–Hinton agar plates with and without cefotaxime (5 mg/L). The plasmid persisted even after the last generation, which indicates that p729 is highly stable. To evaluate the broad host range of the plasmid, Pseudomonas aeruginosa PA01 and Acinetobacter baumannii BM4547 were transformed with the plasmid DNA and selected onto MacConkey agar plates containing ticarcillin (50 mg/L). No transformants were grown for either species tested. Although the IncA/C-type plasmid has a broad host range,6 p729 did not replicate in Pseudomonas or Acinetobacter. All these experiments were carried out under appropriate safety conditions. The ESBLs or AmpC β-lactamases in Salmonella are usually carried on self-transferable plasmids, which could be acquired from other multidrug-resistant Enterobacteriaceae, such as E. coli or Klebsiella pneumoniae.7–9 The blaCMY-2 gene linked with IncA/C-type plasmids has also been frequently reported in isolates of NTS and other Enterobacteriaceae in different geographical regions of the world.6 However, the horizontal transfer and interspecies spread of a plasmid encoding blaCMY-2 were reported for Salmonella Hadar and E. coli.8 The same authors have also detected plasmids with an identical restriction pattern among Salmonella, E. coli and K. pneumoniae isolates and have suggested that it occurs among them.9 Furthermore, the blaCMY-2/CMY-like gene carried by IncA/C plasmids has been repeatedly identified in carbapenem-resistant isolates of E. coli, K. pneumoniae and other Enterobacteriaceae in India (K. K., unpublished data). Therefore we can assume that the IncA/C plasmid carrying the blaCMY-2 gene in Salmonella Typhi might have been acquired from multidrug-resistant Enterobacteriaceae. However, to our knowledge, this is the first report of a Salmonella Typhi isolate producing CMY-2 AmpC β-lactamase. The blaCMY-2 gene associated with ISEcp1 found on a transmissible plasmid in typhoidal Salmonella is a cause for serious concern, as this insertion element facilitates the mobilization and expression of CMY-2-mediated resistance. This is alarming, since the dissemination of such strains with acquired resistance further limits the therapeutic options for typhoid fever. In this context, the use of cephalosporins in the treatment of salmonellosis in paediatric cases will have to be curtailed, making the treatment more difficult. Measures such as improved food, personal hygiene and appropriate antibiotic therapy could help prevent the spread of such resistant strains. The study was carried out as part of our routine work. None to declare.
No takes yet. Share an insight, caveat, or question.
Kumarasamy et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: